OPRX Stock Overview
A digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
OptimizeRx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.28 |
| 52 Week High | US$16.65 |
| 52 Week Low | US$3.78 |
| Beta | 1.35 |
| 1 Month Change | -3.12% |
| 3 Month Change | -26.67% |
| 1 Year Change | -63.10% |
| 3 Year Change | -91.61% |
| 5 Year Change | -47.09% |
| Change since IPO | -97.93% |
Recent News & Updates
Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost
Dec 15
Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?
Nov 16Recent updates
Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost
Dec 15Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?
Nov 16OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
Jul 30OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
Jan 09Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)
Aug 24OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely
Aug 16Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?
May 31OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio
Oct 12Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?
Sep 23OptimizeRx extends reach with Cooler Screens Partnership
Jul 26OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
Jun 27The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business
Nov 16Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All
Aug 13Shareholder Returns
| OPRX | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 9.3% | -1.9% | 0.6% |
| 1Y | -63.1% | -1.3% | 23.7% |
Return vs Industry: OPRX underperformed the US Healthcare Services industry which returned -1.3% over the past year.
Return vs Market: OPRX underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| OPRX volatility | |
|---|---|
| OPRX Average Weekly Movement | 15.2% |
| Healthcare Services Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OPRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OPRX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 136 | Will Febbo | www.optimizerx.com |
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.
OptimizeRx Corporation Fundamentals Summary
| OPRX fundamental statistics | |
|---|---|
| Market cap | US$93.76m |
| Earnings (TTM) | -US$24.17m |
| Revenue (TTM) | US$88.18m |
1.1x
P/S Ratio-4.0x
P/E RatioIs OPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPRX income statement (TTM) | |
|---|---|
| Revenue | US$88.18m |
| Cost of Revenue | US$32.98m |
| Gross Profit | US$55.20m |
| Other Expenses | US$79.37m |
| Earnings | -US$24.17m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.31 |
| Gross Margin | 62.59% |
| Net Profit Margin | -27.41% |
| Debt/Equity Ratio | 30.8% |
How did OPRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 23:25 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OptimizeRx Corporation is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Constantine Davides | JMP Securities |
| Eric Martinuzzi | Lake Street Capital Markets, LLC |